CGON
CG Oncology·NASDAQ
--
--(--)
--
--(--)
4.76 / 10
Netural
Fund flow analysis scores 7.64/10, indicating robust fund flow characteristics. Bullish trends in Small contrast with bearish signals in overall, block, Medium, Large, and Extra-large, suggesting positive liquidity momentum. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(33.3%), Buy(66.7%) across 3 coverage providers, supported by 1.89 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
33%
Buy
67%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-12
InstitutionTruist Securities
Times predicted3
Historical Win Rate0.0%
Is money flowing into or out of CGON?
- CGON holds a Bearish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.76/10 (Netural).
